Metabolic abnormalities and body composition of HIV-infected children on Lopinavir or Nevirapine-based antiretroviral therapy

Archives of Disease in Childhood

Volumn 98, Issue 4, 2013, Pages 258-264

  Arpadi, Stephen ^a,b   Shiau, Stephanie ^a,b   Strehlau, Renate ^c   Martens, Leigh ^c   Patel, Faeezah ^c   Coovadia, Ashraf ^c   Abrams, Elaine J ^b,d   Kuhn, Louise ^a,b  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b Columbia University ^*  (United States)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LAMIVUDINE; LOPINAVIR; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; STAVUDINE; TRIACYLGLYCEROL; LOW DENSITY LIPOPROTEIN;

ARTICLE; BODY COMPOSITION; BODY FAT; BODY FAT DISTRIBUTION; CHILDHOOD DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSULIN SENSITIVITY; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; METABOLIC DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKINFOLD; SOUTH AFRICA; CHILD; CLINICAL ASSESSMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; LIPOATROPHY; LIPOHYPERTROPHY; LIPOPROTEIN BLOOD LEVEL; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ANTI-HIV AGENTS; BODY COMPOSITION; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; INFANT; INSULIN RESISTANCE; LAMIVUDINE; LIPIDS; LOPINAVIR; MALE; NEVIRAPINE; RITONAVIR; SOUTH AFRICA; STAVUDINE;

EID: 84876187057     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/archdischild-2012-302633     Document Type: Article

References (45)

1. Carter RJ, Wiener J, Abrams EJ, et al. Dyslipidemia among perinatally HIV-infected children enrolled in the PACTS-HOPE cohort, 1999-2004: a longitudinal analysis. J Acquir Immune Defic Syndr 2006;41:453.
2. Aldrovandi GM, Lindsey JC, Jacobson DL, et al. Morphologic and metabolic abnormalities in vertically HIV-infected children and youth. AIDS 2009;23:661.
3. Strehlau R, Coovadia A, Abrams EJ, et al. Lipid profiles in young HIV-infected children initiating and changing antiretroviral therapy. J Acquir Immune Defic Syndr 2012;60:369-76.
4. Sztam KA, Jiang H, Jurgrau A, et al. Early increases in concentrations of total, LDL, and HDL cholesterol in HIV-infected children following new exposure to antiretroviral therapy. J Pediatr Gastroenterol Nutr 2011;52:495.
5. Jaquet D, Lévine M, Ortega-Rodriguez E, et al. Clinical and metabolic presentation of the lipodystrophic syndrome in HIV-infected children. AIDS 2000;14:2123.
6. Dimock D, Thomas V, Cushing A, et al. Longitudinal assessment of metabolic abnormalities in adolescents and young adults with HIV-infection acquired perinatally or in early childhood. Metabolism 2011;60:874-80.
7. Chantry CJ, Hughes MD, Alvero C, et al. Lipid and glucose alterations in HIV-infected children beginning or changing antiretroviral therapy. Pediatrics 2008.
8. Bitnun A, Sochett E, Dick PT, et al. Insulin Sensitivity and beta-cell function in protease inhibitor-treated and-naive human immunodeficiency virus-infected children. J Clin Endocrinol Metab 2005;90:168.
9. Noor MA, Seneviratne T, Aweeka FT, et al. Indinavir acutely inhibits insulin-stimulated glucose disposal in humans: a randomized, placebo-controlled study. AIDS 2002;16:F1.
10. Ben-Romano R, Rudich A, Török D, et al. Agent and cell-type specificity in the induction of insulin resistance by HIV protease inhibitors. AIDS 2003;17:23.
11. Innes S, Levin L, Cotton M. Lipodystrophy syndrome in HIV-infected children on HAART. South Afr J HIV Med 2009;10:76.
12. European Paediatric Lipodystrophy Group. Antiretroviral therapy, fat redistribution and hyperlipidaemia in HIV-infected children in Europe. AIDS 2004;18:1443-51.
13. Jacobson DL, Patel K, Siberry GK, et al. Body fat distribution in perinatally HIV-infected and HIV-exposed but uninfected children in the era of highly active antiretroviral therapy: outcomes from the Pediatric HIV/AIDS Cohort Study. Am J Clin Nutr 2011;94:1485-95.
14. Daniels SR, Morrison JA, Sprecher DL, et al. Association of body fat distribution and cardiovascular risk factors in children and adolescents. Circulation 1999;99:541-5.
15. Sanchez TAM, Munoz MR, Madero R, et al. Prevalence of fat redistribution and metabolic disorders in human immunodeficiency virus-infected children. Eur J Pediatr 2005;164:271-6.
16. Alam N, Cortina-Borja M, Goetghebuer T, et al. Body fat abnormality in HIV-infected children and adolescents living in Europe: prevalence and risk factors: fat abnormality in children. J Acquir Immune Defic Syndr 2012;59:314-24.
17. Mallewa JE, Wilkins E, Vilar J, et al. HIV-associated lipodystrophy: a review of underlying mechanisms and therapeutic options. J Antimicrob Chemother 2008;62:648-60.
18. WHO. Towards universal access: scaling up priority HIV/AIDS interventions in the health sector. 2010.
19. Coovadia A, Abrams EJ, Stehlau R, et al. Reuse of nevirapine in exposed HIV-infected children after protease inhibitor-based viral suppression: a randomized controlled trial. JAMA 2010;304:1082-90.
20. South African National Department of Health. South African Guidelines, Factsheet Section 10, Antiretroviral. 2007. http://www.doh.gov.za/docs/ factsheets/guidelines/hiv/part5.pdf (accessed Aug 2011).
21. WHO. Child growth standards and WHO anthro and macros. 2007. http://www.who.int/childgrowth/en/(accessed May 2011).
22. Kaelber DC, Pickett F. Simple table to identify children and adolescents needing further evaluation of blood pressure. Pediatrics 2009;123:e972.
23. Daniels S, Greer F. Lipid screening and cardiovascular health in childhood. Pediatrics 2008;122:198.
24. Kavey REW, Daniels SR, Lauer RM, et al. American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation 2003;107:1562.
25. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003;107:499-511.
26. American Diabetes Association. Type 2 diabetes in children and adolescents. Diabetes Care 2000;23:381-9.
27. Keskin M, Kurtoglu S, Kendirci M, et al. Homeostasis model assessment is more reliable than the fasting glucose/insulin ratio and quantitative insulin sensitivity check index for assessing insulin resistance among obese children and adolescents. Pediatrics 2005;115:e500.
28. Rolland-Cachera M, Brambilla P, Manzoni P, et al. Body composition assessed on the basis of arm circumference and triceps skinfold thickness: a new index validated in children by magnetic resonance imaging. Am J Clin Nutr 1997;65:1709.
29. Van Lenthe FJ, Kemper HCG, Van Mechelen W, et al. Development and tracking of central patterns of subcutaneous fat in adolescence and adulthood: the Amsterdam Growth and Health Study. Int J Epidemiol 1996;25:1162.
30. Horlick M, Arpadi SM, Bethel J, et al. Bioelectrical impedance analysis models for prediction of total body water and fat-free mass in healthy and HIV-infected children and adolescents. Am J Clin Nutr 2002;76:991.
31. Aurpibul L, Puthanakit T, Lee B, et al. Lipodystrophy and metabolic changes in HIV-infected children on non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy. Antivir Ther 2007;12:1247-54.
32. Purnell JQ, Zambon A, Knopp RH, et al. Effect of ritonavir on lipids and post-heparin lipase activities in normal subjects. AIDS 2000;14:51-7.
33. Nicklas T, Von Duvillard S, Berenson G. Tracking of serum lipids and lipoproteins from childhood to dyslipidemia in adults: the Bogalusa Heart Study. Int J Sports Med 2002;23(s 1):39-43.
34. Berenson GS, Srinivasan SR, Bao W, et al. Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults. N Engl J Med 1998;338:1650.
35. Li S, Chen W, Srinivasan SR, et al. Childhood cardiovascular risk factors and carotid vascular changes in adulthood. JAMA 2003;290:2271.
36. Deeks SG. HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med 2011;62:141-55.
37. Ross AC, Storer N, Ann OR. Longitudinal changes in carotid intima-media thickness and cardiovascular risk factors in human immunodeficiency virus-infected children and young adults compared with healthy controls. Pediatr Infect Dis J 2010; 29:634.
38. Cook DG, Mendall MA, Whincup PH, et al. C-reactive protein concentration in children: relationship to adiposity and other cardiovascular risk factors. Atherosclerosis 2000;149:139-50.
39. Guimaraes MM, Greco DB, Figueiredo SM, et al. High-sensitivity C-reactive protein levels in HIV-infected patients treated or not with antiretroviral drugs and their correlation with factors related to cardiovascular risk and HIV infection. Atherosclerosis 2008;201:434-9.
40. Arpadi SM, Bethel J, Horlick M, et al. Longitudinal changes in regional fat content in HIV-infected children and adolescents. AIDS 2009;23:1501.
41. Dzwonek AB, Lawson MS, Cole TJ, et al. Body fat changes and lipodystrophy in HIV-infected children: impact of highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2006;43:121-3.
42. Ammassari A, Antinori A, Cozzi-Lepri A, et al. Relationship between HAART adherence and adipose tissue alterations. J Acquir Immune Defic Syndr 2002;31: S140.
43. WHO. Antiretroviral therapy for HIV infection in infants and children: towards universal access. recommendations for a Public Health Approach, 2010 revision. Geneva, Switzerland. World Health Organization, 2010.
44. Squires KE. An Introduction: to nucleoside and nucleotide analogues. Antivir Ther 2001;6(Suppl 3):1-14.
45. Mobius U, Lubach-Ruitman M, Castro-Frenzel B, et al. Switching to atazanavir improves metabolic disorders in antiretroviral-experienced patients with severe hyperlipidemia. J Acquir Immune Defic Syndr 2005;39:174-80.